Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: Current status and future perspective

Journal of Ethnopharmacology

Volumn 140, Issue 3, 2012, Pages 519-525

  Zhang, Li ^a   Yan, Jingbo ^b   Liu, Xinmin ^c   Ye, Zuguang ^d   Yang, Xiaohui ^b   Meyboom, Ronald ^e   Chan, Kelvin ^f,g   Shaw, Debbie ^h   Duez, Pierre ⁱ  

^a SFDA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF WESTERN SYDNEY   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

China; Pharmacovigilance; Risk management; Safety monitoring; Traditional Chinese Medicine drug

Indexed keywords

CHINESE DRUG; HERBACEOUS AGENT; NATURAL PRODUCT;

CHINA; CHINESE MEDICINE; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MONITORING; DRUG SAFETY; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; HERBAL MEDICINE; INTERNATIONAL COOPERATION; ORGANIZATION; PATIENT COMPLIANCE; QUALITY CONTROL; REVIEW; RISK FACTOR; RISK MANAGEMENT; STANDARDIZATION; TRADITIONAL MEDICINE;

EID: 84862777002     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2012.01.058     Document Type: Article

References (20)

1. Anastassiades, M., Fernandez-Alba, A.R., 2009. Analysis of Nicotine in Mushrooms, http://www.crl-pesticides.eu/library/docs/srm/meth-NicotineMushrooms- CrlFvCrlSrm.pdf (accessed November 2011).
2. Chan, K., Zhang, H.W., Lin, Z.X., 2011. Treatments used in complementary and alternative medicine. In: Aaron, J.K. (Ed.), Side effects of Drugs Annual, vol. 33. Elsevier, Amsterdam, The Netherlands, pp. 989-1007.
3. Du, W., Guo, J.J., Jing, Y., Li, X., Kelton, C.M.L., 2008. Drug safety surveillance in china and other countries: a review and comparison. Value in Health 11, S130-S136. (Pubitemid 351490469)
4. Guo, J., Pan, J., 2003. A case report of chronic arsenic intoxication and melanoderma caused by long-term overdose of NiuhuangJieduPian. China Occupational Medicining 30, 7.
5. Hu, J., Shang, H., Li, J., Zhang, L., Zhang, J., Zhen, W., Li, T., Zhang, B., Li, Y., 2010. Adverse drug reactions linked to Ciwujia injection: a systematic review of 521 cases. Journal of Evidence Based Medicine 3, 37-43.
6. Jiang, M., Lu, C., Zhang, C., Yang, J., Tan, Y., Lu, A., Chan, K., 2012. Syndrome differentiation in modern research of traditional Chinese medicine. J. Ethnopharmacol. 140, 634-642.
7. Jing, Y., Kelton, C.M.L., Li, X., Guo, J.J., 2007. Lethal drug probe in China: the case of Xinfu clindamycin. Pharmacoepidemiology and Drug Safety 16, 928-932. (Pubitemid 47322591)
8. Liu, J., Shi, J.-Z., Yu, L.M., Goyer, R.A., Waalkes, M.P., 2008. Mercury in traditional medicines: is cinnabar toxicologically similar to common mercurials? Experimental Biology and Medicine (Maywood) 233, 810-817.
9. MOH, SFDA, 2010. Good Manufacturing Practice for Drugs (2010 Revision), http://eng.sfda.gov.cn/WS03/CL0768/65113.html (accessed January 2012).
10. MOH, SFDA, 2011. Adverse drug reation reporting and monitoring provision, http://www.sfda.gov.cn/WS01/CL0053/62621.html (accessed January 2012).
11. SFDA, 2002. Good Agricultural Practice for Chinese Crude Drugs (Interim), http://eng.sfda.gov.cn/WS03/CL0768/61642.html (accessed January 2012).
12. SFDA, 2011. SFDA releases 2010 Annual Report on National Adverse Drug Reaction Monitoring. China Pharmaceutical Newsletter 4, pp. 5-6. http://www.ccpie.org/news/download/2011pharm-4.pdf (accessed January 2011).
13. State Administration of TCM of the People's Republic of China, 2010. Notice on printing and distributing Guidelines on the Clinical Application of TCM. SATCM-MA No. 30.
14. SFDA, 2003. Notice on the termination of the medicinal use of Guan Mutong. SFDAREGISTRATION No. 121.
15. SFDA, 2004. Notice on Suspension of the manufacturing approval applications and clinical use of Yuxingcao injection and 7 other related injections. SFDA-SAFETY No. 217.
16. The Ministry of Health, SFDA, SATCM, 2008. Notice on further strengthening the production, management and clinical rational use of TCMI. MOH-MA No. 71.
17. UMC, 2012. http://www.who-umc.org/graphics/24727.pdf (accessed 24.01.12).
18. WHO, 2003. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants, http://whqlibdoc.who.int/publications/ 2003/9241546271.pdf (accessed January 2012).
19. Zhang, L., Yang, X.H., 2009. Pharmacovigilance should be introduced into the safety monitoring and evaluation of traditional Chinese drugs. Journal of Integrated Traditional Western Medicine 29, 863-866.
20. Zhao, Z., Liang, Z., Chan, K., Lu, G., Lee, E., Chen, H., Li, L., 2010. A unique issue in the standardization of Chinese material medica: processing. Planta Medica 76, 1975-1986.